Embecta Faces Securities Fraud Lawsuit Following Stock Plunge
Embecta Corp. is facing a securities fraud class action lawsuit alleging the company misled investors about the strength of its insulin pen needle product category. The suit follows a significant stock price drop for the medical device company.
A securities fraud class action lawsuit has been filed against Embecta Corp. and certain of its senior executives in the U.S. District Court for the District of New Jersey. The action alleges violations of federal securities laws, stemming from claims that the company misled investors regarding its financial performance and the health of its insulin pen needle business, leading to a substantial drop in its stock price.
The complaint asserts that during the relevant period, Embecta made positive statements about its insulin pen portfolio, describing it as resilient. However, the lawsuit alleges that Embecta was, in reality, facing significant competition and experiencing softness in the overall market for insulin pens and pen needles.
Embecta's stock price fell by approximately 57.8% on May 5, 2026. This decline occurred after the company announced disappointing second-quarter results, citing share losses in its pen needle category, partly due to a single customer, and acknowledging an overall market volume softness for insulin pens. The company also reduced its quarterly dividend significantly.
Investors who purchased Embecta common stock and suffered losses are encouraged to seek more information. The deadline for potential lead plaintiffs to apply to the court to lead the case is August 17, 2026. The lawsuit, captioned Apitz-Grossman v. Embecta Corp., aims to recover damages for investors harmed by the alleged misrepresentations.